Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in non-small cell lung cancer
- Trial result Spotlight
Non-small cell lung cancer
Pralsetinib (Selective RET TKI): ctDNA Clearance Flags 12-mo + PFS in RET-Fusion NSCLC
Pralsetinib, an oral CNS-penetrant RET tyrosine-kinase inhibitor, was evaluated in a single-arm prospective biomarker study of 21 Chinese patients with advanced RET-fusion NSCLC (Phase 2 ARROW, NCT03037385). Baseline…
NCT03037385 - Trial result
Non-small cell lung cancer
Consolidative SRT After 1L Chemo-IO Yields 29-mo mPFS in Oligo-Residual NSCLC (Phase 2)
Stereotactic radiotherapy (SRT) to all oligo-residual lesions was delivered while continuing maintenance systemic therapy after effective first-line chemo-immunotherapy in a single-arm study from China (driver…
NCT04767009 - New trial Spotlight
Non-small cell lung cancer
Phase II Trial: Dato-DXd, TROP2-directed ADC in advanced NSCLC
This Phase II study at AstraZeneca and select centers evaluates three sub-studies in advanced or metastatic NSCLC. It tests rilvegostomig—a Tigit and PD-1 bispecific mAb—with ramucirumab, a VEGFR2-directed antibody,…
NCT07098338 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 2b trial of Visugromab, anti‐GDF15 monoclonal antibody, in metastatic NSCLC
CatalYm GmbH sponsors a multi-part Phase 2b study comparing visugromab with pembrolizumab, pemetrexed, and carboplatin versus placebo plus standard immunochemotherapy. The trial targets first-line treatment for…
NCT07098988 Exploratory - Trial result
Non-small cell lung cancer
Durvalumab + Oleclumab (CD73) or Monalizumab (NKG2A) Lowers PFS Hazard ≈40% in Unresectable Stage III NSCLC
Durvalumab, an anti‑PD‑L1 antibody, was paired with oleclumab (anti‑CD73) or monalizumab (anti‑NKG2A) in the open‑label phase 2 COAST trial (NCT03822351) enrolling 189 patients with unresectable stage III NSCLC and…
NCT03822351 - Trial result
Non-small cell lung cancer
Encorafenib + Binimetinib (BRAF/MEK) Delivers 75% ORR and 30 mo PFS in BRAF V600E mNSCLC
Encorafenib, a BRAF inhibitor, plus the MEK inhibitor binimetinib was tested in the single‑arm Phase 2 PHAROS study (NCT03915951), treating 59 untreated and 39 previously treated BRAF V600E‑mutant metastatic NSCLC…
NCT03915951 - New trial Spotlight
Non-small cell lung cancer
Phase 2/3 trial of BMS-986504, a selective MTA-cooperative PRMT5 inhibitor in metastatic NSCLC
This randomized study compares BMS-986504 combined with pembrolizumab and chemotherapy versus placebo regimens in first-line metastatic non-small cell lung cancer patients with homozygous MTAP deletion. BMS-986504…
NCT07063745 Registrational - New trial Spotlight
Non-small cell lung cancer
Phase I CVHNLC mRNA immunotherapy plus pembrolizumab PD-1 inhibitor study in metastatic sqNSCLC
This open-label, first-in-human trial by CureVac evaluates safety and tolerability of investigational CVHNLC—an mRNA therapy intended to trigger anti-tumor immune responses—in combination with pembrolizumab and, in…
NCT07073183 First-in-human - New trial
Non-small cell lung cancer
Phase III Trial: Durvalumab with AZD6738 ATR inhibitor in NSCLC adjuvant setting
This randomized Phase III trial by the National Cancer Institute evaluates whether adding AZD6738, an ATR inhibitor that blocks DNA damage repair, to standard durvalumab improves time without recurrence in patients…
NCT06732401 Registrational - New trial
Non-small cell lung cancer
Phase 2: Raludotatug Deruxtecan, CDH6‐targeted ADC with an enzymatically cleavable linker
This randomized umbrella study by Merck Sharp & Dohme LLC assesses two investigational ADCs—raludotatug deruxtecan (CDH6-directed) and ifinatamab deruxtecan (B7-H3-targeting Topo1 toxin ADC)—versus docetaxel in…
NCT06780085 Exploratory - Trial result
Non-small cell lung cancer
Gut-Targeted Vancomycin Boosts SBRT Survival in Early-Stage NSCLC
Vancomycin, a non-absorbed antibiotic that selectively depletes gram-positive gut bacteria, was paired with stereotactic body radiotherapy (SBRT) in a randomized pilot (NCT03546829) of medically inoperable stage I–II…
NCT03546829 - Trial result
Non-small cell lung cancer
Divarasib Delivers 56% ORR and ~14 mo PFS in KRAS G12C NSCLC
Divarasib (GDC-6036) is an oral, covalent KRAS G12C inhibitor; targeting the ~11‑13% of NSCLC tumors that carry this mutation; in the GO42144 Phase I dose-escalation/expansion trial (NCT04449874) 65 previously…
NCT04449874 - New trial Spotlight
Non-small cell lung cancer
Phase 2 Trial of Raludotatug deruxtecan ADC targeting CDH6
In this randomized umbrella study under a pembrolizumab master protocol, participants with previously treated Stage IV squamous NSCLC receive treatments every 3 weeks until disease progression. Investigational arms…
NCT06780098 Exploratory - New trial
Non-small cell lung cancer
Phase 1 NK-102: Umbilical Cord Blood NK Cells with Soluble IL-15 & PD-L1 Expression
This Phase 1 dose escalation trial by University of California, Irvine examines the safety and maximum tolerated dose of NK-102, an engineered natural killer cell therapy expressing soluble IL-15 and PD-L1,…
NCT07053007 First-in-human - New trial
Non-small cell lung cancer
Phase 2 Tiragolumab (TIGIT mAb) and Ivonescimab (PD-1/VEGF bispecific) trial in lung SCC.
This Phase 2 study at M.D. Anderson Cancer Center evaluates the combination of tiragolumab—a TIGIT-directed monoclonal antibody—and ivonescimab—a bispecific antibody targeting PD-1 and VEGF—in patients with…
NCT07038915 Exploratory - Trial result
Non-small cell lung cancer
Platinum Doublet Lifts 2-Year DFS to 96% in Gene-High Stage I–IIA NSCLC
Platinum-based adjuvant chemotherapy—mainly cisplatin or carboplatin doublets—was tested in the Phase 3 AIM-HIGH trial (NCT01817192), which randomized 200 resected stage IA-IIA non-squamous NSCLC patients flagged as…
NCT01817192 - New trial Spotlight
Non-small cell lung cancer
Phase 2 study of Telisotuzumab Vedotin, c‑Met–targeted ADC with tubulin inhibitor, in NSCLC
AbbVie is testing telisotuzumab vedotin—a c‑Met–targeted antibody-drug conjugate with a tubulin inhibitor—in adults with previously treated, c-Met-overexpressing, EGFR-wild-type, advanced non-squamous NSCLC—a…
NCT06568939 Exploratory - New trial
Non-small cell lung cancer
Phase II GT103 mAb targeting complement factor H with pembrolizumab for STK11 NSCLC
This study tests GT103 with pembrolizumab as a combination immunotherapy for advanced STK11 mutant non‐small cell lung cancer. Sponsored by Roswell Park Cancer Institute, the trial evaluates GT103’s novel complement…
NCT07017829 Exploratory - Trial result Spotlight
Non-small cell lung cancer
Perioperative PD-1 Blockade (Nivolumab) + Chemo Pushes 30-mo EFS to 61% in Resectable NSCLC
Nivolumab, an anti-PD-1 antibody, given with four neoadjuvant platinum-doublet cycles and up to a year of adjuvant monotherapy (CheckMate 77T, n = 461 stage IIA–IIIB) achieved median event-free survival of 46.6 mo vs…
- Trial result
Non-small cell lung cancer
RiskReveal 14-Gene Assay Guides Platinum Adjuvant to 96% 2-Year DFS in Stage IA–IIA NSCLC
RiskReveal, a 14-gene expression panel, stratified 421 resected stage IA–IIA non-squamous NSCLC patients; intermediate/high-risk cases (mITT n=194 [46%]) were randomized to 4 cycles of cisplatin-based adjuvant…
- New trial
Non-small cell lung cancer
Phase II: Durvalumab PD-L1 inhibitor with Tremelimumab CTLA-4 inhibitor and chemotherapy
This trial by Georgetown University evaluates the safety and efficacy of platinum-based chemotherapy combined with durvalumab and tremelimumab, followed by durvalumab maintenance, in HIV-positive patients with stage…
NCT04499053 Exploratory - Trial result
Non-small cell lung cancer
Telisotuzumab Vedotin (c-Met ADC) shows 100% ORR in KRAS G12C patients and doubled survival in 2L+ MET-high EGFRwt NSCLC
Telisotuzumab vedotin (Teliso-V), a c-Met-targeted ADC bearing the MMAE payload, was given at 1.9 mg/kg Q2W to 83 2nd line+, EGFR-wild-type, c-Met-overexpressing non-squamous NSCLC patients in LUMINOSITY Stage 2…
NCT03539536 - Trial result
Non-small cell lung cancer
Temab-A (ABBV-400) monotherapy hits 63% ORR in heavily pre-treated EGFR-mutant NSCLC— similar to triple combo benchmark
Temab-A is a c-Met–targeting antibody–drug conjugate armed with a novel topoisomerase-1 inhibitor. In the phase 1 dose-expansion cohort (NCT05029882), 41 EGFR-mutated, advanced non-squamous NSCLC patients who had…
NCT05029882 - Trial result
Non-small cell lung cancer
Glecirasib Hits 48% ORR and 8.2-Month PFS in KRAS G12C NSCLC Phase 2b
Glecirasib (JAB-21822), a covalent oral KRAS G12C inhibitor, was evaluated in the single-arm Phase 2b NCT05009329. 119 previously treated Chinese patients with locally advanced/metastatic KRAS G12C NSCLC received 800…
NCT05009329 - New trial
Non-small cell lung cancer
Phase 3 trial: Belrestotug (TIGIT mAb) plus Dostarlimab (PD-1 inhibitor) in PD-L1 high NSCLC.
This randomized, multicenter, double‑blind study compares belrestotug, a TIGIT monoclonal antibody, and dostarlimab, a PD‑1 inhibitor, versus pembrolizumab plus placebo for first‑line treatment of unresectable,…
NCT06472076 Registrational - New trial
Non-small cell lung cancer
Phase II trial of Zimberelimab, a PD-1 inhibitor, in advanced NSCLC immunotherapy combinations.
This open-label platform study evaluates objective response and safety of various immunotherapy regimens in advanced non-small cell lung cancer. Investigational arms pair zimberelimab (a PD-1 inhibitor) with…
NCT05676931 - New trial
Non-small cell lung cancer
Phase II trial of Fingolimod, a sphingosine‐1‐phosphate receptor modulator, in advanced NSCLC and SCLC.
This single-institution, open-label study evaluates daily oral fingolimod 0.5 mg in patients with advanced NSCLC or SCLC who have progressed on chemo-immunotherapy. A six-patient safety lead-in precedes expansion…
NCT06424067 Exploratory - Trial result
Non-small cell lung cancer
Sigvotatug vedotin (IB6 ADC) + pembrolizumab hits 57% ORR in PD-L1⁺ NSCLC
Sigvotatug vedotin, an integrin β6–directed vedotin ADC, was paired with pembrolizumab in the Phase 1 SGNB6A-001 escalation/expansion trial (NCT04389632). Thirty-one patients with advanced NSCLC (n = 19) or HNSCC (n…
NCT04389632 - Trial result
Non-small cell lung cancer
Datopotamab Deruxtecan (TROP2-ADC) + Pembrolizumab Delivers 55–56% ORR and 20-Month DoR in First-Line Advanced NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody–drug conjugate, was paired with the PD-1 inhibitor pembrolizumab ± platinum chemotherapy in the Phase 1b/2 TROPION-Lung02 trial (NCT04526691). Among 96…
NCT04526691 - Trial result
Non-small cell lung cancer
ctDNA Sequencing Flags KEAP1, STK11 & NOTCH as Frequent Drivers of ICI Resistance in NSCLC
In a prospective two-cohort study (STING + COPE; n = 57) that collected plasma before therapy and at radiographic progression, investigators used an FDA-approved 500-gene ctDNA panel to profile resistance mechanisms…
NCT04932525
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.